Xunlei Limited (XNET)

Xunlei reported strong Q2 2025 financial performance with total revenues of $104.0 million, representing a 30.6% year-over-year increase. The company highlighted significant gains from its investment in Arashi Vision and successful acquisition of Hupu, with net income reaching $727.4 million.

Gainers Recruiter.com Group, Inc. (NASDAQ: RCRT) shares jumped 114% to $0.41. Recruiter.com signed a definitive agreement for planned purchase of fintech assets of GoLogiq. Hoth Therapeutics, Inc. (NASDAQ: HOTH) rose 96% to $3.6850 after the company announced preclinical results for HT-ALZ for the treatment of Alzheimer's disease. Visionary Education Technology Holdings Group Inc. (NASDAQ: VEDU) shares rose 37.8% to $0.5928. Zura Bio Limited (NASDAQ: ZURA) shares gained 25% to $8.11 after the company completed approximately $80 million financing with the focus on advancing ZB-106, a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist. Xunlei Limited (NASDAQ: XNET) rose 22% to $1.6715. Xunlei launched a $20 million share buyback program. G-III Apparel Group, Ltd. (NASDAQ: GIII) gained 21.7% to $20.13 following first-quarter results. G-III Apparel reported a master licensing partnership with Xcel Brands to design and produce all categories and distribute products globally for the Halston business and all of its brands. GT Biopharma, Inc. (NASDAQ: GTBP) rose 20.7% to $0.35. Secoo Holding Limited (NASDAQ: SECO) gained 20.2% to $0.9739. GitLab Inc. (NASDAQ: GTLB) shares climbed 19.9% to $42.43 after the company reported better-than-expected first-quarter results. Multiple analysts raised their price targets on the stock following the report. Big Lots, Inc. (NYSE: BIG) gained 18.1% to $6.97. Chijet Motor Company, Inc. (NASDAQ: TTOO) shares surged 18.1% to $0.0827after dipping around 31% on Monday. T2 Biosystems reported submission for the FDA breakthrough device designation for candida auris diagnostic test. Castle Biosciences, Inc. (NASDAQ: CSTL) gained 18.8% to $13.86. Canaccord Genuity maintained Castle Biosciences with a Buy and lowered the price target from $60 to $40. Novo ...